{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-035376","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.625029+00:00","generated_at":"2026-06-04T09:10:46.064065+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences FY2023 net loss narrows to $0.1M; cash $12.0M through 2024","bullets":["Year-end cash $12.0M vs $5.3M; company believes sufficient to fund operations through 2024.","Net loss for FY2023 $0.1M (EPS -$0.53) vs $10.8M loss ($149.20 EPS) in 2022, due to $8.3M warrant liability gain.","Q4 2023 net loss $2.2M ($8.33 EPS) vs $1.2M loss ($15.61 EPS) in Q4 2022; operating cash burn $2.0M.","Completed $6.2M public offering; began Phase 1 study of Gemini; presented positive preclinical AKI data.","Net cash used in operations for FY2023 was $7.3M, down from $11.2M in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-035376","json":"https://secwatch.observer/filing/0000950170-24-035376.json","markdown":"https://secwatch.observer/filing/0000950170-24-035376.md","text":"https://secwatch.observer/filing/0000950170-24-035376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024035376/0000950170-24-035376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024035376/revb-20240322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:10:46.064065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28b653f62827e410d4250d4d420ad95b24db028f","claim":"REVELATION BIOSCIENCES, INC. reported twelve months ended December 31, 2023 results: net income net loss of $0.1 million, EPS $0.53 basic and diluted net loss per share.","evidence_excerpt":"Revelation’s net loss for the three and twelve months ended December 31, 2023 was $2.2 million and $0.1 million, or $8.33 and $0.53 basic and diluted net loss per share, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024035376/0000950170-24-035376-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve months ended December 31, 2023"},{"label":"Net income","value":"net loss of $0.1 million"},{"label":"EPS","value":"$0.53 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d267b36a0d55b577140d0ab305b6c029581db2b4","claim":"REVELATION BIOSCIENCES, INC. reported three months ended December 31, 2023 results: net income net loss of $2.2 million, EPS $8.33 basic and diluted net loss per share.","evidence_excerpt":"Revelation’s net loss for the three and twelve months ended December 31, 2023 was $2.2 million and $0.1 million, or $8.33 and $0.53 basic and diluted net loss per share, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017024035376/0000950170-24-035376-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2023"},{"label":"Net income","value":"net loss of $2.2 million"},{"label":"EPS","value":"$8.33 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}